Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Allergan : to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 10:25am CET

Release date- 03102017 - DUBLIN - Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the open of the U.S. Financial Markets.

Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, November 1, 2017 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 65879759.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion, and will remain available through 11:30 p.m. Eastern Time on December 1, 2017. The replay may be accessed by dialing (855) 859-2056 and entering the conference ID 65879759. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same conference ID.

To access the webcast, please visit Allergan's Investor Relations website at ttps://www.allergan.com/inves.... A replay of the webcast will also be available on Allergan's Investor Relations website.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan'scurrent perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDAapprovals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergandisclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas

Tel: (862) 261-8006

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
03/15ALLERGAN : Trademark Application for "NORCO" Filed
03/09ALLERGAN : Senators seek to end sovereign immunity in patent cases
03/08ALLERGAN : to Present at The Cowen and Company 38th Annual Health Care Conferenc..
03/08INSIDER TRADING ACTIVITY ALLERGAN PL : AGN) – CFO Bought 1,000 shares of S..
03/08INSIDER TRADING ACTIVITY ALLERGAN PL : AGN) – CEO Bought 3,300 shares of S..
03/06ALLERGAN : Mohawk tribe to appeal IPR case
03/06ALLERGAN : Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Ano..
03/01ALLERGAN : Researchers at Allergan Target Veterinary Ophthalmology (Bimatoprost ..
03/01GLOBAL INHALATION & NASAL SPRAY GENE : 99strategy added a depth and professional..
02/28ALLERGAN : to Present at The Barclays Global Healthcare Conference
More news
News from SeekingAlpha
03/15Desperate Allergan Seeks 'Sense Of Urgency' 
03/14Allergan continues up move, investors warm to management's "sense of urgency".. 
03/11Few Spared In Global Market Sell-Off 
03/09Key events next week - healthcare (continued #2) 
03/08Opioid settlement talks hit roadblocks 
Financials ($)
Sales 2018 15 199 M
EBIT 2018 7 277 M
Net income 2018 -289 M
Debt 2018 22 898 M
Yield 2018 1,75%
P/E ratio 2018 -
P/E ratio 2019 102,07
EV / Sales 2018 5,12x
EV / Sales 2019 4,78x
Capitalization 54 873 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 214 $
Spread / Average Target 29%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC1.55%54 873
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965